Efficacy of imatinib maintenance after stem cell transplantation for Ph+/ BCR:: ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease [0.03%]
伊马替尼巩固移植后治疗费城染色体阳性急性淋巴细胞白血病的疗效：一项随机研究的长期结局及其移植前后的微小残留病的影响
Heike Pfeifer,Wolfgang Bethge,Stefan Schönland et al.
Heike Pfeifer et al.
Tyrosine kinase inhibitors are recommended as maintenance therapy following allogeneic stem cell transplantation (HSCT) for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but optimal medication, dose, and duratio...
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study [0.03%]
维奈克拉和低甲基化药物与其它疗法的比较：一项国际多中心回顾队列研究
Jacqueline S Garcia,Pinkal Desai,Joshua F Zeidner et al.
Jacqueline S Garcia et al.
Venetoclax (VEN) plus hypomethylating agents (HMA) is approved for newly diagnosed (ND) acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy (IC). This international retrospective chart review involving 17 academic...
Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort [0.03%]
针对复发或难治性多发性骨髓瘤的双特异性抗体和CAR-T细胞治疗的真实世界分析：一项全球TriNetX发现队列和当代验证队列的研究
Theo Leitner,Lorenz Oelschläger,Francisco Henriquez Mosquera et al.
Theo Leitner et al.
Bispecific antibodies (BsAbs) and BCMA-directed CAR-T cell therapies have transformed late-line relapsed/refractory multiple myeloma (RRMM), yet real-world comparisons are confounded by treatment selection, line of therapy, and supportive c...
Transfusion-Independent iron overload in SF3B1-mutant myelodysplastic syndrome case report [0.03%]
SF3B1突变型骨髓增生异常综合征相关输血独立性铁过载病例报告
Ashik Zala,Simone Claudiani,Simona Deplano
Ashik Zala
Multidisciplinary approach to early identification of inborn errors of immunity in patients with lymphoproliferation [0.03%]
淋巴增生患者先天性免疫缺陷的早期诊断的多学科方法
Laia Alsina,Verónica Celis Passini,Carmen Garrido Colino et al.
Laia Alsina et al.
Inborn errors of immunity (IEIs) comprise a broader spectrum of manifestations than primary immunodeficiencies (PID). They often present with immune dysregulation manifestations such as lymphoproliferation (LP), a common yet underrecognized...
Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel [0.03%]
Axicabtagene Ciloleucel治疗复发/难治性大B细胞淋巴瘤的临床结局、与健康相关的生活质量和医疗费用及资源利用的系统文献回顾
Yi Lin,Madhu Palivela,Pardis Lakzadeh et al.
Yi Lin et al.
The approval of axicabtagene ciloleucel (axi-cel) for use in second-line (2L) relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emerging real-world evidence provides clinical and economic insights. We conducted a systematic review of ...
Real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron database [0.03%]
美国Flatiron数据库复发/难治多发性骨髓瘤患者二线、三线及四线治疗的现实世界治疗模式和临床结局数据分析
Maria J Nieto,Yu-Hsuan Shih,Jiaqi Fang et al.
Maria J Nieto et al.
This study assessed real-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma (RRMM) who received second- (2 L), third- (3 L), and fourth-line (4 L) treatments. Among 3910 patients who rece...
Exploring risk factors for attributable mortality from fusariosis in hematological malignancy patients [0.03%]
探索造血系统恶性肿瘤患者归因于 fusariosis 的死亡率的风险因素
David Schantz,Gayathri Krishnan,Anupam Pande
David Schantz
We explored risk factors for attributable mortality in proven invasive Fusarium infections among patients with hematological malignancies, which remain poorly defined. This single-center retrospective study included adult patients with hema...
Keying Chen,Maria-Myrsini Tzioni,Zi Chen et al.
Keying Chen et al.
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies [0.03%]
S64315（一种静脉注射型MCL1抑制剂）治疗血液系统恶性肿瘤患者的I期临床试验
Norbert Vey,Olga Salamero,Ashish Bajel et al.
Norbert Vey et al.
Preclinical data support myeloid cell leukemia 1 (MCL1) inhibition in the treatment of acute myeloid leukemia (AML). Patients with relapsed/refractory myelodysplastic syndrome (n = 1) or AML (n = 32) or older patients with untreated AML ine...